Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature..
SARS-CoV-2 has emerged as a significant cause of morbidity and mortality worldwide. Virus neutralization assays are critical for the development and evaluation of vaccines and immunotherapeutics, as well as for conducting basic research into the immune response, spread, and pathogenesis of this disease. However, neutralization assays traditionally require the use of infectious virus which must be carefully handled in a BSL-3 setting, thus complicating the assay and restricting its use to labs with access to BSL-3 facilities. Pseudovirus-based assays are an alternative to the use of infectious virus. SARS-CoV-2 pseudovirus contains only the spike structural protein, and infection results in a single round of replication, thus allowing for the assay to be run safely under BSL-2 conditions. In this chapter, we describe protocols and considerations for the production and titration of lentivirus-based SARS-CoV-2 pseudovirus, as well as for running and analysis of FACS-based pseudovirus neutralization assays.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2452 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2452(2022) vom: 10., Seite 361-378 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Balinsky, Corey [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.05.2022 Date Revised 13.06.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-2111-0_21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34080890X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34080890X | ||
| 003 | DE-627 | ||
| 005 | 20231226010317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-2111-0_21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM34080890X | ||
| 035 | |a (NLM)35554917 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Balinsky, Corey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2022 | ||
| 500 | |a Date Revised 13.06.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a SARS-CoV-2 has emerged as a significant cause of morbidity and mortality worldwide. Virus neutralization assays are critical for the development and evaluation of vaccines and immunotherapeutics, as well as for conducting basic research into the immune response, spread, and pathogenesis of this disease. However, neutralization assays traditionally require the use of infectious virus which must be carefully handled in a BSL-3 setting, thus complicating the assay and restricting its use to labs with access to BSL-3 facilities. Pseudovirus-based assays are an alternative to the use of infectious virus. SARS-CoV-2 pseudovirus contains only the spike structural protein, and infection results in a single round of replication, thus allowing for the assay to be run safely under BSL-2 conditions. In this chapter, we describe protocols and considerations for the production and titration of lentivirus-based SARS-CoV-2 pseudovirus, as well as for running and analysis of FACS-based pseudovirus neutralization assays | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antibody | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Lentivirus | |
| 650 | 4 | |a Neutralization | |
| 650 | 4 | |a Protocols | |
| 650 | 4 | |a Pseudovirus (PV) | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Spike | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Jani, Vihasi |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Peifang |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Defang, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Porter, Kevin R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2452(2022) vom: 10., Seite 361-378 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2452 |g year:2022 |g day:10 |g pages:361-378 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-2111-0_21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2452 |j 2022 |b 10 |h 361-378 | ||